Calamos Advisors
PFE icon

Calamos Advisors’s Pfizer PFE Stock Holding History

Calamos Advisors’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-969,680
Closed -$39.1M – 771
2019
Q1 		$39.1M Buy
+969,680
New +$38.8M 0.24% 126

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Calamos Advisors's PFE Position: Q1 2026 in Review

Calamos Advisors reduced its Pfizer (PFE) stake by 5.9% in Q1 2026, selling an estimated $3.02M and leaving 1,805,659 shares worth $50.7M. The position accounts for 0.18% of the portfolio, ranked #129.

Calamos Advisors first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $146M in Q2 2019. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Calamos Advisors held 1,805,659 shares of Pfizer worth $50.7M as of Q1 2026.
  • Calamos Advisors sold 113,617 Pfizer shares in Q1 2026, an estimated $3.02M.
  • Pfizer made up 0.18% of Calamos Advisors's portfolio in Q1 2026, its #129 holding.
  • Calamos Advisors first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Calamos Advisors's Pfizer position peaked at $146M in Q2 2019.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.